The proposed Phase 1 study will be a randomized, placebo-controlled trial assessing the safety, tolerability, and pharmacokinetics of RBD3133 when administered subcutaneously to participants struggling with weight management. By targeting the INHBE gene, which encodes activin E, the drug mimics naturally occurring loss-of-function variants that have been linked in genetic studies to healthier fat distribution and a reduced risk of type 2 diabetes and coronary heart disease.

Dr. Anders Gabrielsen, Chief Medical Officer at Ribo, stated that the filing translates human genetic evidence into potential RNAi-based medicine. As the company's first obesity-focused candidate, RBD3133 serves as a cornerstone for their broader cardiovascular and metabolic pipeline, addressing a global health crisis that affects over one billion people. The trial is expected to establish the foundational data necessary for the future development of the therapeutic, which the firm intends to position as a durable solution for metabolic dysfunction.